

Didier Betbeder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3547226/publications.pdf>

Version: 2024-02-01

71
papers

2,733
citations

159585

30
h-index

182427

51
g-index

73
all docs

73
docs citations

73
times ranked

4047
citing authors

#	ARTICLE	IF	CITATIONS
1	Starch nanoparticles improve curcumin-induced production of anti-inflammatory cytokines in intestinal epithelial cells. <i>International Journal of Pharmaceutics</i> , 2022, 4, 100114.	1.6	7
2	Intranasal vaccine from whole <i>Leishmania donovani</i> antigens provides protection and induces specific immune response against visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009627.	3.0	11
3	Effective Nanoparticle-Based Nasal Vaccine Against Latent and Congenital Toxoplasmosis in Sheep. <i>Frontiers in Immunology</i> , 2020, 11, 2183.	4.8	24
4	Importance of the Phospholipid Core for Mucin Hydrogel Penetration and Mucosal Cell Uptake of Maltodextrin Nanoparticles. <i>ACS Applied Bio Materials</i> , 2020, 3, 5741-5749.	4.6	11
5	Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine. <i>International Journal of Pharmaceutics</i> , 2020, 582, 119348.	5.2	7
6	Protein delivery by porous cationic maltodextrin-based nanoparticles into nasal mucosal cells: Comparison with cationic or anionic nanoparticles. <i>International Journal of Pharmaceutics</i> : X, 2019, 1, 100001.	1.6	13
7	Stabilization of Human Tyrosine Hydroxylase in Maltodextrin Nanoparticles for Delivery to Neuronal Cells and Tissue. <i>Bioconjugate Chemistry</i> , 2018, 29, 493-502.	3.6	7
8	Porous Maltodextrin-Based Nanoparticles: A Safe Delivery System for Nasal Vaccines. <i>Journal of Nanomaterials</i> , 2018, 2018, 1-8.	2.7	7
9	Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections. <i>Frontiers in Immunology</i> , 2018, 9, 2060.	4.8	25
10	Residence time and uptake of porous and cationic maltodextrin-based nanoparticles in the nasal mucosa: Comparison with anionic and cationic nanoparticles. <i>International Journal of Pharmaceutics</i> , 2018, 550, 316-324.	5.2	25
11	Preparation and characterization of novel chitosan and β -cyclodextrin polymer sponges for wound dressing applications. <i>Carbohydrate Polymers</i> , 2017, 173, 535-546.	10.2	51
12	Development and validation of a reversed-phase HPLC method for the quantification of paclitaxel in different PLGA nanocarriers. <i>Electrophoresis</i> , 2017, 38, 2536-2541.	2.4	8
13	Synthetic parasites: a successful mucosal nanoparticle vaccine against <i>Toxoplasma</i> congenital infection in mice. <i>Future Microbiology</i> , 2017, 12, 393-405.	2.0	22
14	Solubilization of β -galactosylceramide in aqueous medium: Impact on Natural Killer T cell activation and antitumor responses. <i>International Journal of Pharmaceutics</i> , 2017, 530, 354-363.	5.2	9
15	Nasal nanovaccines. <i>International Journal of Pharmaceutics</i> , 2017, 530, 128-138.	5.2	66
16	Vectorization by nanoparticles decreases the overall toxicity of airborne pollutants. <i>PLoS ONE</i> , 2017, 12, e0183243.	2.5	4
17	Influence of the surface charge of PLGA nanoparticles on their <i>in vitro</i> genotoxicity, cytotoxicity, ROS production and endocytosis. <i>Journal of Applied Toxicology</i> , 2016, 36, 434-444.	2.8	73
18	Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles. <i>Journal of Controlled Release</i> , 2016, 232, 42-50.	9.9	47

#	ARTICLE	IF	CITATIONS
19	Evolution of availability of curcumin inside poly-lactic-co-glycolic acid nanoparticles: impact on antioxidant and antinitrosant properties. <i>International Journal of Nanomedicine</i> , 2015, 10, 5355.	6.7	15
20	Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic <i>Toxoplasma gondii</i> infection. <i>Biomaterials</i> , 2015, 50, 164-175.	11.4	61
21	HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis. <i>Vaccine</i> , 2014, 32, 6240-6250.	3.8	31
22	Development of innovative paclitaxel-loaded small PLGA nanoparticles: Study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. <i>International Journal of Pharmaceutics</i> , 2013, 454, 712-719.	5.2	58
23	Airway delivery of peptides and proteins using nanoparticles. <i>Biomaterials</i> , 2013, 34, 516-525.	11.4	59
24	Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. <i>Vaccine</i> , 2013, 31, 2628-2637.	3.8	31
25	Influence of surface charge and inner composition of nanoparticles on intracellular delivery of proteins in airway epithelial cells. <i>Biomaterials</i> , 2012, 33, 9117-9126.	11.4	30
26	Transferrin Adsorption onto PLGA Nanoparticles Governs Their Interaction with Biological Systems from Blood Circulation to Brain Cancer Cells. <i>Pharmaceutical Research</i> , 2012, 29, 1495-1505.	3.5	95
27	Activation of invariant Natural Killer T lymphocytes in response to the α -galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles. <i>International Journal of Pharmaceutics</i> , 2012, 423, 45-54.	5.2	43
28	Study of serum interaction with a cationic nanoparticle: Implications for in vitro endocytosis, cytotoxicity and genotoxicity. <i>International Journal of Pharmaceutics</i> , 2012, 423, 37-44.	5.2	54
29	Drug delivery systems in the treatment of African trypanosomiasis infections. <i>Expert Opinion on Drug Delivery</i> , 2011, 8, 735-747.	5.0	18
30	Development of transferrin functionalized poly(ethylene glycol)/poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma. <i>Journal of Materials Science: Materials in Medicine</i> , 2010, 21, 2673-2681.	3.6	47
31	Positively-Charged, Porous, Polysaccharide Nanoparticles Loaded with Anionic Molecules Behave as "Stealth" Cationic Nanocarriers. <i>Pharmaceutical Research</i> , 2010, 27, 126-133.	3.5	48
32	Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. <i>Nanotechnology</i> , 2010, 21, 355102.	2.6	100
33	Development of a nanoparticulate formulation of diminazene to treat African trypanosomiasis. <i>Nanotechnology</i> , 2010, 21, 505102.	2.6	30
34	Formulation and characterization of polyphenol-loaded lipid nanocapsules. <i>International Journal of Pharmaceutics</i> , 2009, 379, 270-277.	5.2	185
35	Preface. <i>International Journal of Pharmaceutics</i> , 2009, 379, 199-200.	5.2	1
36	Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. <i>International Journal of Pharmaceutics</i> , 2009, 379, 285-292.	5.2	247

#	ARTICLE	IF	CITATIONS
37	Letter to the Editor. <i>Vaccine</i> , 2009, 27, 3691.	3.8	0
38	Drug delivery to the brain using colloidal carriers. <i>Progress in Brain Research</i> , 2009, 180, 2-17.	1.4	9
39	Targeting the Allergen to Dendritic Cells with Mucoadhesive Formulations Enhances Tolerance Induction Via the Sublingual Route. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, S14-S14.	2.9	0
40	Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 603-609.e5.	2.9	119
41	Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. <i>Vaccine</i> , 2008, 26, 6555-6563.	3.8	68
42	Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 278-285.	2.9	104
43	Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. <i>International Journal of Pharmaceutics</i> , 2007, 344, 103-109.	5.2	128
44	Effect of high-intensity interval training and detraining on extra $\dot{V}O_{2}$ and on the $\dot{V}O_{2}$ slow component. <i>European Journal of Applied Physiology</i> , 2007, 99, 633-640.	2.5	15
45	Effect of prior heavy exercise on muscle deoxygenation kinetics at the onset of subsequent heavy exercise. <i>European Journal of Applied Physiology</i> , 2007, 99, 677-684.	2.5	12
46	Effect of Prior Exercise on the $\dot{V}O_{2}$ /Work Rate Relationship During Incremental Exercise and Constant Work Rate Exercise. <i>International Journal of Sports Medicine</i> , 2006, 27, 345-350.	1.7	9
47	Effects of β - and Hydroxypropyl- β -cyclodextrins on the Transport of Doxorubicin across an in Vitro Model of Blood-Brain Barrier. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 1115-1120.	2.5	48
48	Enhancement of Protective Efficacy following Intranasal Immunization with Vaccine Plus a Nontoxic LTK63 Mutant Delivered with Nanoparticles. <i>Infection and Immunity</i> , 2002, 70, 4785-4790.	2.2	57
49	Design and Antileishmanial Activity of Amphotericin B-Loaded Stable Ionic Amphiphile Biovector Formulations. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1597-1601.	3.2	23
50	Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. <i>Vaccine</i> , 2002, 20, 2752-2763.	3.8	98
51	IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy. <i>Cytotherapy</i> , 2002, 4, 11-19.	0.7	8
52	A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration. <i>European Journal of Cancer</i> , 2001, 37, 1053-1060.	2.8	20
53	Ex Vivo Stimulation and Expansion of both CD4 + and CD8 + T Cells from Peripheral Blood Mononuclear Cells of Human Cytomegalovirus-Seropositive Blood Donors by Using a Soluble Recombinant Chimeric Protein, IE1-pp65. <i>Journal of Virology</i> , 2001, 75, 7840-7847.	3.4	41
54	Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. <i>Pharmaceutical Research</i> , 2000, 17, 817-824.	3.5	64

#	ARTICLE	IF	CITATIONS
55	Biovector nanoparticles improve antinociceptive efficacy of nasal morphine. <i>Pharmaceutical Research</i> , 2000, 17, 743-748.	3.5	49
56	Separation of dipalmitoyl phosphatidyl choline, cholesterol and their degradation products by high-performance liquid chromatography on a perfluorinated stationary bonded phase. <i>Journal of Chromatography A</i> , 1999, 840, 31-38.	3.7	19
57	New methods to determine the extent of reaction of epichlorohydrin with maltodextrins. <i>Carbohydrate Research</i> , 1999, 319, 17-23.	2.3	30
58	Characterisation and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1997, 1327, 32-40.	2.6	47
59	Structural characterization (shape and dimensions) and stability of polysaccharide/lipid nanoparticles. <i>Biopolymers</i> , 1997, 41, 511-520.	2.4	17
60	Structural characterization of organized systems of polysaccharides and phospholipids by light scattering spectroscopy and electron microscopy. <i>Carbohydrate Research</i> , 1997, 300, 31-40.	2.3	7
61	Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80 nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T-cell clones in vitro. <i>Vaccine</i> , 1996, 14, 511-520.	3.8	22
62	A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens. <i>Vaccine</i> , 1996, 14, 1353-1360.	3.8	21
63	Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors. <i>Vaccine</i> , 1994, 12, 1413-1418.	3.8	20
64	Regiospecific enzymic acylation of butyl β -D-glucopyranoside. <i>Carbohydrate Research</i> , 1993, 243, 407-411.	2.3	9
65	Versatile enzymatic diacid ester synthesis of butyl β -D-glucopyranoside. <i>Tetrahedron</i> , 1993, 49, 10877-10882.	1.9	16
66	Characterization of a benzyl-phenoxy-ethanamine binding protein in <i>Trypanosoma equiperdum</i> and the possible relation between binding affinity and trypanocidal activity. <i>Molecular and Biochemical Parasitology</i> , 1993, 58, 311-316.	1.1	0
67	Improved Synthesis of Sodium Alkyl-Glucopyranuronates. <i>Synthetic Communications</i> , 1993, 23, 1357-1360.	2.1	10
68	Production of homogeneous basic fibroblast growth factor by specific enzymatic hydrolysis of larger microheterogeneous molecular forms. <i>Journal of Biotechnology</i> , 1991, 21, 83-92.	3.8	4
69	Enzymatic Synthesis of Dideoxyribonucleosides. <i>Nucleosides & Nucleotides</i> , 1991, 10, 465-468.	0.5	11
70	The stereoselective enzymatic synthesis of 9- β -D-2-deoxyribofuranosyl 1-deazapurine. <i>Nucleic Acids Research</i> , 1989, 17, 4217-4222.	14.5	36
71	Antimicrobials. New nitrofurans derivatives. <i>Journal of Medicinal Chemistry</i> , 1973, 16, 281-287.	6.4	19